First study drug for relapsed AML or MDS
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can sign consent and follow study visits and blood/bone marrow sample schedules.
- You have confirmed relapsed or refractory AML or MDS (and you’ve already tried approved treatments, or you can’t tolerate them).
- Your white blood cell count is under 20,000 at the first dose (hydroxyurea is allowed), and may need to be rechecked before later doses.
- Your general condition is good enough for treatment (ECOG performance status 0–2).
- Your kidney and liver blood tests meet limits (creatinine clearance ≥60; bilirubin and liver enzyme levels within allowed ranges).
- You do NOT have certain exclusions (for example: acute promyelocytic leukemia, active CNS leukemia, recent transplant or immune-suppression, recent immune-based treatments, serious uncontrolled infection, or known HIV/hepatitis with active infection).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests an experimental drug called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a protein called CD38 on leukemia cells, and the goal is to see if it is safe and helpful.
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
This trial tests a new drug (CLN-049) combined with two standard AML medicines (azacitidine and venetoclax) for people who are newly diagnosed with AML and cannot have intensive chemotherapy. It aims to see if this combination is safe and effective for those who are not fit for the usual strong treatment.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.